Lung transplantation for pulmonary hypertension

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 158, 2007, Pages 4-9

  Orens, J B ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROSTACYCLIN; TACROLIMUS;

DYSPNEA; EXERCISE TOLERANCE; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION RISK; LEUKOPENIA; MORBIDITY; NEPHROTOXICITY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TREMOR;

EID: 37249088559     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01617.x     Document Type: Review

References (36)

1. Reitz BA, Wallwork JL, Hunt SA et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982 306 : 557 64.
2. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ. The registry of the International Society for Heart and Lung Transplantation: Fourteenth official report. J Heart Lung Transplant 1997 16 : 691 4.
3. Rubin LJ, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med 1983 99 : 433 8.
4. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987 76 : 135 41.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992 327 : 76 81.
6. Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990 112 : 485 91.
7. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998 17 : 679 85.
8. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol 1995 75 : 63A 6.
9. Gaine SP, Rubin LJ. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci 1998 315 : 179 84.
10. American Thoracic Society: Medical Section of the American Lung Association. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998 158 : 335 9.
11. Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006 25 : 745 55.
12. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991 115 : 343 9.
13. Rich S, Levy PS. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med 1984 76 : 573 8.
14. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987 107 : 216 23.
15. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997 16 : 313 9.
16. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984 70 : 580 7.
17. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994 121 : 409 15.
18. Shapiro SM, Oudiz RJ, Cao T et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997 30 : 343 9.
19. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 334 : 296 302.
20. Whyte RI, Robbins RC, Altinger J et al. Heart-lung transplantation for primary pulmonary hypertension. Ann Thorac Surg 1999 67 : 937 41.
21. Bando K, Armitage JM, Paradis IL et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994 108 : 1056 65.
22. Bando K, Keenan RJ, Paradis IL et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994 58 : 1336 42.
23. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M et al. Single lung transplantation for pulmonary hypertension. Single institution experience in patients. Circulation 1995 92 : 2252 8.
24. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000 19 : 909 31.
25. Levine SM, Jenkinson SG, Bryan CL, Anzueto A, Zamora CA, Gibbons WJ et al. Ventilation46 perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension. Chest 1992 101 : 401 5.
26. Chaparro C, Kesten S. Infections in lung transplant recipients. Clin Chest Med 1997 18 : 339 51.
27. Maurer JR, Tullis DE, Grossman RF et al. Infectious complications following isolated lung transplantation. Chest 1992 101 : 1056 9.
28. Dolonish M, Rossm C, Chambers C et al. Mucociliary function in patients following single or lung-heart transplantation. Am Rev Respir Dis 1987 135 : A363.
29. Armitage J, Kormos R, Stuart R et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991 10 : 877 87.
30. Orens JB, Shearon TH, Freudenberger RS, Conte JV, Bhorade SM, Ardehali A. Thoracic organ transplantation in the United States, 1995-2004. Am J Transplant 2006 6 (5 part 2 1188 97.
31. Trulock EP, Edwards LB, Taylor DO et al. The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report. J Heart Lung Transplant 2003 22 : 625 35.
32. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005 24 : 1454 9.
33. Christie JD, Kotloff RM, Pochettino A et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003 124 : 1232 41.
34. Cooper JD, Billingham M, Egan MI et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts: The International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993 12 : 713 6.
35. Yagi K, Liu C, Bando T et al. Inhibition of reperfusion injury by human thioredoxin (adult T-cell leukemia derived factor) in canine lung transplantation. J Thorac Cardiovasc Surg 1994 108 : 913.
36. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report. J Heart Lung Transplant 1998 17 : 656 68.